Capital Rx, a pharmacy benefit management startup, generated $3.5 billion in revenue last year, capitalizing on the growing scrutiny of traditional PBMs that profit from inflated drug costs. Unlike its larger competitors, Capital Rx operates transparently, charging flat fees rather than profiting off drug price markups. As Congress pushes for greater reform and transparency within the PBM industry, Capital Rx positions itself uniquely for growth, projecting a revenue increase to $4.8 billion by 2025. However, the startup is currently not profitable due to its ongoing investments in technology development.
Transparent pharmacy benefit management startup Capital Rx is gaining momentum, achieving $3.5 billion in revenue by offering a straightforward model amid criticism of traditional PBMs.
Collection
[
|
...
]